PURPOSE: The aim of this study is to investigate the efficacy and safety of gemcitabine and oxaliplatin combination chemotherapy as first-line therapy in patients with inoperable biliary tract cancer (BTC). METHODS: The treatment of this non-randomized phase II study consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on day 1 and oxaliplatin 85 mg/m(2) i.v. on day 2 every 2 weeks until disease progression, unaccep toxicity or patients' refusal. RESULTS: From Sept 2006 to Oct 2007, 40 patients were enrolled. In the ITT analysis, the objective response rate was 15.0% and the disease control rate was 52.5%. The median overall survival (95% CI) was 8.5 months (6.4-10.7) and the time to progression was 4.2 months (0.5-7.9). For the 305 cycles, observed grade 3/4 toxicity was uncommon. CONCLUSIONS: Gemcitabine and dose adjusted oxaliplatin combination chemotherapy had moderate anti-tumor activity and was well tolerated as a first-line treatment for patients with inoperable BTC.
PURPOSE: The aim of this study is to investigate the efficacy and safety of gemcitabine and oxaliplatin combination chemotherapy as first-line therapy in patients with inoperable biliary tract cancer (BTC). METHODS: The treatment of this non-randomized phase II study consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on day 1 and oxaliplatin 85 mg/m(2) i.v. on day 2 every 2 weeks until disease progression, unaccep toxicity or patients' refusal. RESULTS: From Sept 2006 to Oct 2007, 40 patients were enrolled. In the ITT analysis, the objective response rate was 15.0% and the disease control rate was 52.5%. The median overall survival (95% CI) was 8.5 months (6.4-10.7) and the time to progression was 4.2 months (0.5-7.9). For the 305 cycles, observed grade 3/4 toxicity was uncommon. CONCLUSIONS:Gemcitabine and dose adjusted oxaliplatin combination chemotherapy had moderate anti-tumor activity and was well tolerated as a first-line treatment for patients with inoperable BTC.
Authors: Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Kerry J Williams; Joel Picus; Kim Trinkhaus; Chloe C Fournier; Rama Suresh; Joan S James; Benjamin R Tan Journal: HPB (Oxford) Date: 2010-08 Impact factor: 3.647
Authors: Adriana Romiti; Chiara D'Antonio; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Viola Barucca; Valeria Durante; Paolo Marchetti Journal: J Gastrointest Cancer Date: 2012-09
Authors: Sang Myung Woo; Sang Hyub Lee; Ji Won Yoo; Ki Young Yang; Jung Gyun Seo; Joo Kyung Park; Jin-Hyeok Hwang; Woo Jin Lee; Ji Kon Ryu; Yong-Tae Kim; Yong Bum Yoon Journal: Gut Liver Date: 2013-06-11 Impact factor: 4.519
Authors: J S Graham; K Boyd; F Y Coxon; L R Wall; M M Eatock; T S Maughan; M Highley; E Soulis; S Harden; P Bützberger-Zimmerli; T R J Evans Journal: BMC Res Notes Date: 2016-03-12